MRS2395

MRS2395, an dipivaloyl derivative, is a potent P2Y12 receptor antagonist. MRS2395 inhibits ADP-induced platelet activation with a Ki of 3.6 μM. MRS2395 inhibits cAMP induced by ADP in rat platelets in the presence of PGE1 with an IC50 of 7 µM. MRS2395 enhances platelet dense granule release in response to TRAP-6[1][2].

Product Specifications

CAS Number

[491611-55-3]

UNSPSC

12352005

Target

P2Y Receptor

Type

Reference compound

Related Pathways

GPCR/G Protein

Applications

Neuroscience-Neuromodulation

Field of Research

Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/mrs2395.html

Solubility

10 mM in DMSO

Smiles

CNC1=C2N=CN(CC(COC(C(C)(C)C)=O)COC(C(C)(C)C)=O)C2=NC(Cl)=N1

Molecular Formula

C20H30ClN5O4

Molecular Weight

439.94

References & Citations

[1]Bin Xu, et al.Acyclic analogues of adenosine bisphosphates as P2Y receptor antagonists: phosphate substitution leads to multiple pathways of inhibition of platelet aggregation. J Med Chem. 2002 Dec 19;45 (26) :5694-709. |[2]Annachiara Mitrugno, et al. Potentiation of TRAP-6-induced platelet dense granule release by blockade of P2Y 12 signaling with MRS2395. Platelets. 2018 Jun;29 (4) :383-394.